Single User License
INR 102030
Site License
INR 204060
Corporate User License
INR 306090

Service Tax Additional

select a format
Price

Single User License
USD 1500
Site License
USD 3000
Corporate User License
USD 4500

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Vertex Pharmaceuticals Incorporated-Product Pipeline Review-2015

Vertex Pharmaceuticals Incorporated-Product Pipeline Review-2015


  Request for Sample Report

Executive Summary

Vertex Pharmaceuticals Incorporated-Product Pipeline Review-2015

Summary

Global Markets Direct's, 'Vertex Pharmaceuticals Incorporated-Product Pipeline Review-2015', provides an overview of the Vertex Pharmaceuticals Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vertex Pharmaceuticals Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides brief overview of Vertex Pharmaceuticals Incorporated including business description, key information and facts, and its locations and subsidiaries

The report reviews current pipeline of Vertex Pharmaceuticals Incorporated's human therapeutic division and enlists all their major and minor projects

The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones

Special feature on out-licensed and partnered product portfolio

The report summarizes all the dormant and discontinued pipeline projects

Latest company statement

Latest news and deals relating to the Vertex Pharmaceuticals Incorporated's pipeline products

Reasons To Buy

Evaluate Vertex Pharmaceuticals Incorporated's strategic position with total access to detailed information on its product pipeline

Assess the growth potential of Vertex Pharmaceuticals Incorporated in its therapy areas of focus

Identify new drug targets and therapeutic classes in the Vertex Pharmaceuticals Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas

Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps

Develop strategic initiatives by understanding the focus areas of Vertex Pharmaceuticals Incorporated and exploit collaboration and partnership opportunities

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vertex Pharmaceuticals Incorporated

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Explore the dormant and discontinued projects of Vertex Pharmaceuticals Incorporated and identify potential opportunities in those areas

Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Vertex Pharmaceuticals Incorporated Snapshot 6

Vertex Pharmaceuticals Incorporated Overview 6

Key Information 6

Key Facts 6

Vertex Pharmaceuticals Incorporated-Research and Development Overview 7

Key Therapeutic Areas 7

Vertex Pharmaceuticals Incorporated-Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products-Monotherapy 11

Pipeline Products-Combination Treatment Modalities 12

Pipeline Products-Out-Licensed Products 13

Out-Licensed Products/Combination Treatment Modalities 14

Vertex Pharmaceuticals Incorporated-Pipeline Products Glance 15

Vertex Pharmaceuticals Incorporated-Late Stage Pipeline Products 15

Pre-Registration Products/Combination Treatment Modalities 15

Phase III Products/Combination Treatment Modalities 16

Vertex Pharmaceuticals Incorporated-Clinical Stage Pipeline Products 17

Phase II Products/Combination Treatment Modalities 17

Phase I Products/Combination Treatment Modalities 18

Vertex Pharmaceuticals Incorporated-Early Stage Pipeline Products 19

Preclinical Products/Combination Treatment Modalities 19

Discovery Products/Combination Treatment Modalities 20

Vertex Pharmaceuticals Incorporated-Drug Profiles 21

(lumacaftor + ivacaftor) 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

(VX-661 + ivacaftor) 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

decernotinib 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

VX-210 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

VX-970 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

telaprevir 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

VX-803 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

Small Molecule to Inhibit HSP90 alpha/beta for Huntington's Disease 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Small Molecules to Inhibit Protein Kinase for Tuberculosis 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

VE-465 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

VE-821 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

VE-822 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

VXc-486 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Next Generation Correctors 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

Small Molecule to Antagonize CGRP Receptor for Migraine 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Small Molecule to Inhibit PI3K Gamma for Undisclosed Indications 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Small Molecules for Cancer 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

Small Molecules for Multiple Sclerosis 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

VT-12008911 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

Vertex Pharmaceuticals Incorporated-Pipeline Analysis 50

Vertex Pharmaceuticals Incorporated-Pipeline Products by Target 50

Vertex Pharmaceuticals Incorporated-Pipeline Products by Route of Administration 52

Vertex Pharmaceuticals Incorporated-Pipeline Products by Molecule Type 53

Vertex Pharmaceuticals Incorporated-Pipeline Products by Mechanism of Action 54

Vertex Pharmaceuticals Incorporated-Recent Pipeline Updates 55

Vertex Pharmaceuticals Incorporated-Dormant Projects 63

Vertex Pharmaceuticals Incorporated-Discontinued Pipeline Products 64

Discontinued Pipeline Product Profiles 64

ALS-2158 64

pralnacasan 64

VX-745 64

VX-759 64

VX-983 65

Vertex Pharmaceuticals Incorporated-Company Statement 66

Vertex Pharmaceuticals Incorporated-Locations And Subsidiaries 71

Head Office 71

Other Locations & Subsidiaries 71

Appendix 73

Methodology 73

Coverage 73

Secondary Research 73

Primary Research 73

Expert Panel Validation 73

Contact Us 73

Disclaimer 74

List of Tables

Vertex Pharmaceuticals Incorporated, Key Information 6

Vertex Pharmaceuticals Incorporated, Key Facts 6

Vertex Pharmaceuticals Incorporated-Pipeline by Indication, 2015 9

Vertex Pharmaceuticals Incorporated-Pipeline by Stage of Development, 2015 10

Vertex Pharmaceuticals Incorporated-Monotherapy Products in Pipeline, 2015 11

Vertex Pharmaceuticals Incorporated-Combination Treatment Modalities in Pipeline, 2015 12

Vertex Pharmaceuticals Incorporated-Out-Licensed Products in Pipeline, 2015 13

Vertex Pharmaceuticals Incorporated-Out-Licensed Products/ Combination Treatment Modalities, 2015 14

Vertex Pharmaceuticals Incorporated-Pre-Registration, 2015 15

Vertex Pharmaceuticals Incorporated-Phase III, 2015 16

Vertex Pharmaceuticals Incorporated-Phase II, 2015 17

Vertex Pharmaceuticals Incorporated-Phase I, 2015 18

Vertex Pharmaceuticals Incorporated-Preclinical, 2015 19

Vertex Pharmaceuticals Incorporated-Discovery, 2015 20

Vertex Pharmaceuticals Incorporated-Pipeline by Target, 2015 51

Vertex Pharmaceuticals Incorporated-Pipeline by Route of Administration, 2015 52

Vertex Pharmaceuticals Incorporated-Pipeline by Molecule Type, 2015 53

Vertex Pharmaceuticals Incorporated-Pipeline Products by Mechanism of Action, 2015 54

Vertex Pharmaceuticals Incorporated-Recent Pipeline Updates, 2015 55

Vertex Pharmaceuticals Incorporated-Dormant Developmental Projects,2015 63

Vertex Pharmaceuticals Incorporated-Discontinued Pipeline Products, 2015 64

Vertex Pharmaceuticals Incorporated, Other Locations 71

Vertex Pharmaceuticals Incorporated, Subsidiaries 72

List of Figures

Vertex Pharmaceuticals Incorporated-Pipeline by Top 10 Indication, 2015 8

Vertex Pharmaceuticals Incorporated-Pipeline by Stage of Development, 2015 10

Vertex Pharmaceuticals Incorporated-Monotherapy Products in Pipeline, 2015 11

Vertex Pharmaceuticals Incorporated-Combination Treatment Modalities in Pipeline, 2015 12

Vertex Pharmaceuticals Incorporated-Out-Licensed Products in Pipeline, 2015 13

Vertex Pharmaceuticals Incorporated-Pipeline by Top 10 Target, 2015 50

Vertex Pharmaceuticals Incorporated-Pipeline by Top 10 Route of Administration, 2015 52

Vertex Pharmaceuticals Incorporated-Pipeline by Top 10 Molecule Type, 2015 53

Vertex Pharmaceuticals Incorporated-Pipeline Products by Top 10 Mechanism of Action, 2015 54

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Current R&D Portfolio of Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals Incorporated - Key Therapeutics; Vertex Pharmaceuticals Incorporated - Pipeline Overview and Promising Molecules; Vertex Pharmaceuticals Incorporated - News; Vertex Pharmaceuticals Incorporated - Latest Updates; Vertex Pharmaceuticals Incorporated - Pipeline; Vertex Pharmaceuticals Incorporated - Discontinued/Dormant Projects


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com